Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drug makers are targeting flu virus vulnerabilities to develop antivirals that not only stop infections in their tracks, but also temper emergence of drug resistance.
See what grabbed our readers in 2018. It was a year when CRISPR-ed plants, therapies and babies stole the headlines, but there are also some surprises on this list.